By: IPP Bureau
Last updated : January 16, 2023 8:15 am
The company will respond to these observations within the stipulated time period.
Granules India Limited Gagillapur facility located at Hyderabad, Telangana, India has completed the USFDA’s Pre-Approval Inspection (PAI) from 9th January 2023 to 13th January 2023 with three observations.
The company will respond to these observations within the stipulated time period.
Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) for the company.